1. Nucleoporin Nup155 is part of the p53 network in liver cancer.
- Author
-
Holzer K, Ori A, Cooke A, Dauch D, Drucker E, Riemenschneider P, Andres-Pons A, DiGuilio AL, Mackmull MT, Baßler J, Roessler S, Breuhahn K, Zender L, Glavy JS, Dombrowski F, Hurt E, Schirmacher P, Beck M, and Singer S
- Subjects
- Animals, Carcinoma, Hepatocellular genetics, Cell Line, Tumor, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Datasets as Topic, Gene Expression Regulation, Neoplastic, Humans, Liver Neoplasms genetics, Liver Neoplasms, Experimental genetics, Liver Neoplasms, Experimental pathology, Methyltransferases metabolism, Mice, Nuclear Pore Complex Proteins genetics, Nuclear Proteins metabolism, RNA, Small Interfering metabolism, Carcinoma, Hepatocellular pathology, Cyclin-Dependent Kinase Inhibitor p21 genetics, Liver Neoplasms pathology, Methyltransferases genetics, Nuclear Pore Complex Proteins metabolism, Nuclear Proteins genetics, Tumor Suppressor Protein p53 metabolism
- Abstract
Cancer-relevant signalling pathways rely on bidirectional nucleocytoplasmic transport events through the nuclear pore complex (NPC). However, mechanisms by which individual NPC components (Nups) participate in the regulation of these pathways remain poorly understood. We discover by integrating large scale proteomics, polysome fractionation and a focused RNAi approach that Nup155 controls mRNA translation of p21 (CDKN1A), a key mediator of the p53 response. The underlying mechanism involves transcriptional regulation of the putative tRNA and rRNA methyltransferase FTSJ1 by Nup155. Furthermore, we observe that Nup155 and FTSJ1 are p53 repression targets and accordingly find a correlation between the p53 status, Nup155 and FTSJ1 expression in murine and human hepatocellular carcinoma. Our data suggest an unanticipated regulatory network linking translational control by and repression of a structural NPC component modulating the p53 pathway through its effectors.
- Published
- 2019
- Full Text
- View/download PDF